Bio-Techne Corp Stock Price, News & Analysis

ScaleReady has awarded a G-Rex Grant of $200,000 to Dr. Eric Tran of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute. The grant will support process development and IND enabling studies for a novel KRAS-targeted TCR-T cell therapy.

Dr. Tran plans to optimize the manufacturing process by reducing duration and implementing fully-closed system G-Rex bioreactors. The project will utilize Bio-Techne's new GMP cytokines, designed for one-touch G-Rex close process manufacturing.

The G-Rex Grant Program is a $20M initiative by ScaleReady to advance cell and gene-modified cell therapy development and manufacturing. Recipients gain access to support from G-Rex Grant Partners, offering expertise in cGMP manufacturing, quality and regulatory affairs, and CGT business operations.

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $300,000 G-Rex® Grant to Dr. Christopher A. Klebanoff, a renowned cancer immunologist at Memorial Sloan Kettering Cancer Center (MSK). The grant will support the development of a novel CD8α/β-armored TCR-T cell therapy targeting an HLA-A*11:01-restricted RAS (G12D) public neoantigen for a Phase 1 clinical trial.

The grant will provide enabling reagents for process development, IND-enabling studies, and clinical manufacturing. Dr. Klebanoff's team plans to incorporate Wilson Wolf's fully closed-system G-Rex bioreactors and the GatheRex for cell processing. The project aims to develop a robust manufacturing framework for generating infusion products for cancer patients, potentially benefiting those with treatment options.

As part of the grant, MSK will receive early access to Bio-Techne's new line of closed system GMP reagents, including the G-Rex ProPak™ CAR-TCR Cytokine Kits, designed for use with G-Rex bioreactors.

Bio-Techne (NASDAQ: TECH) announced a partnership between its spatial biology brand, Lunaphore, and Discovery Life Sciences (Discovery). The collaboration aims to integrate Lunaphore's COMET™ platform into Discovery's global suite of biospecimen products and specialty lab services for clinical research.

The partnership combines COMET technology, a fully-automated, high-throughput, hyperplex platform for tissue profiling, with Discovery's scientific expertise. This collaboration is expected to advance research in immuno-oncology, immunology, neuroscience, and infectious diseases across all development stages.

Discovery's new Lunaphore COMET Hyperplex Immunofluorescence Services will support the development of next-generation assays for clinical trials and provide multidimensional spatial biology insights. The partnership aims to accelerate biomarker discovery, patient stratification, and translational medicine.

Bio-Techne (NASDAQ: TECH) will showcase its neuroscience research solutions at Neuroscience 2024, the Society for Neuroscience (SfN) annual meeting, from October 5-9, 2024, in Chicago. The company will present its portfolio of life science reagents, immunoassays, automated proteomic instruments, and multiomics solutions at booth #1165.

Key highlights include:

• A nanosymposium on brain senescence using the RNAscope™ Multiomic LS assay
• A poster on antibody validation for the COMET™ spatial biology platform
• A Product Theater presentation with FUJIFILM Cellular Dynamics on Alzheimer's disease intracellular signaling using Simple Western™ technology
• Multiple poster presentations on topics such as pTau217 quantification, synaptic research, interneuron heterogeneity, and glioblastoma biomarker evaluation

Bio-Techne's CEO, Kim Kelderman, emphasized the company's commitment to advancing neuroscience research and enabling next-generation therapies.

Bio-Techne (NASDAQ: TECH) has released its 2024 Corporate Sustainability Report (CSR), highlighting progress in Environmental, Social, and Governance (ESG) initiatives. The report focuses on four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment.

Key developments include:

• Submitting a commitment to reduce Scope 1, 2, and 3 greenhouse gas emissions
• Completing the first EcoVadis sustainability assessment, earning a Bronze Medal
• Continuing to prioritize innovation and community enrichment

CEO Kim Kelderman emphasized the company's dedication to responsible growth and delivering products for advancing therapeutics, vaccines, and diagnostics. The CSR is available on Bio-Techne's website in the Corporate and Social Responsibility section.

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $250,000 G-Rex® Grant to ImmunoScape Pte. This grant will support ImmunoScape's process development and IND enabling studies for their novel WT1-targeted TCR-T cell therapy. The grant includes access to Wilson Wolf's G-Rex® bioreactors and Bio-Techne's new ProPak™ GMP Cytokines, designed to streamline reagent preparation and reduce costs in GMP manufacturing.

ImmunoScape plans to use the grant for pre-clinical process development, technology transfer to their CDMO partner, and generating data for an FDA IND submission planned for 2026. The G-Rex Grant Program, a $20M initiative by ScaleReady, aims to advance cell and gene-modified cell therapy development and manufacturing.

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $150,000 G-Rex Grant to Verismo Therapeutics, a clinical-stage CAR T company. This grant, part of ScaleReady's $20 million program, aims to optimize the development and manufacturing of Verismo's KIR-CAR platform using G-Rex technology.

The grant will support Verismo in transitioning their active and future pipeline to G-Rex, enhancing efficiency and cost-effectiveness in cell therapy production. As part of the grant, Verismo will evaluate critical reagents from Bio-Techne, including GMP cytokines and the new ProPak GMP Cytokines line, estimated to be commercially available by the end of 2024.

Verismo Therapeutics, a clinical-stage CAR T company, has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant will support the optimization of Verismo's KIR-CAR platform development and manufacturing using the G-Rex technology. The grant is part of ScaleReady's $20 million program aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing.

As part of the grant, Verismo will optimize their G-Rex-based KIR-CAR T process and implement it as a platform manufacturing process. The company will also evaluate critical reagents from Bio-Techne, including GMP cytokines and the new ProPakTM GMP cytokines line, estimated to be commercially available by the end of 2024.

ScaleReady and Bio-Techne (NASDAQ: TECH) have launched G-Rex optimized ProPak™ GMP Cytokines, designed for efficient closed system cell and gene-modified cell therapy (CGT) manufacturing. The product consists of a weldable bag with liquid formulated GMP-grade cytokines (IL-7 or IL-15) for CAR-T and TCR-T cell production. Each ProPak™ contains enough cytokines to dose a 1-liter G-Rex bioreactor at 10ng/mL concentration.

This innovation aims to reduce operating costs and complexity in CGT manufacturing by simplifying the process of acquiring, storing, preparing, and administering critical reagents. The product eliminates the need for cytokine reconstitution, enabling a hands-off ballroom style G-Rex manufacturing approach.